These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
39 related articles for article (PubMed ID: 17664453)
1. CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Lexchin J; Gagnon MA Global Health; 2014 May; 10():30. PubMed ID: 24885309 [TBL] [Abstract][Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. 't Hoen E Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298 [No Abstract] [Full Text] [Related]
5. Taking TRIPS to India--Novartis, patent law, and access to medicines. Mueller JM N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473 [No Abstract] [Full Text] [Related]
6. A tragically naive Canadian law for tragically neglected global health. Attaran A CMAJ; 2007 Jun; 176(12):1726-7. PubMed ID: 17449707 [No Abstract] [Full Text] [Related]
8. [Access for all to quality drugs]. Videau JY Med Trop (Mars); 2002; 62(4):396-400. PubMed ID: 12534178 [TBL] [Abstract][Full Text] [Related]
9. The economics of prescription drug prices, government intervention, and the importation of drugs from Canada. Openshaw MS Nurs Econ; 2005; 23(6):307-11, 279. PubMed ID: 16459902 [TBL] [Abstract][Full Text] [Related]
10. The case for compulsory licensing during COVID-19. Wong H J Glob Health; 2020 Jun; 10(1):010358. PubMed ID: 32509289 [No Abstract] [Full Text] [Related]
11. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines. Tetteh E Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829 [No Abstract] [Full Text] [Related]